Group 1 - The "Tang Pang Zhi Jian" AI obesity model was officially launched on August 23, developed by Tangdu Hospital and Shenzhou Medical Technology Co., Ltd. [3] - This model integrates authoritative medical guidelines and high-quality expert consensus, leveraging clinical resources and research achievements in obesity prevention from Tangdu Hospital, along with Shenzhou Medical's DHC multimodal fusion architecture and medical reasoning engine [5][6] - The core value of the model is to manage obesity patients throughout the entire process, from pre-diagnosis to post-diagnosis, establishing a comprehensive prevention network that includes risk identification, cause classification, and precise management [6] Group 2 - In a recent study published in the journal "Aging-US," Insilico Medicine explored the biological mechanisms related to aging in idiopathic pulmonary fibrosis (IPF), a chronic lung disease primarily affecting individuals over 60 [8] - The research established a new connection between aging biology and the pathogenesis of IPF, showcasing the potential of AI-driven methods in developing innovative anti-aging treatment solutions [8] - Insilico Medicine plans to validate the AI model through a dedicated IPF patient cohort and expand its methods to other fibrosis and aging-related disease research areas [8] Group 3 - On August 23, Shukun Technology introduced the concept of "AI Native Smart Hospital" at the 2025 Digital Medicine and Health Conference, aiming to create an "AI super brain" for traditional hospitals [10] - This concept is centered around the "Shukun Kun multimodal medical health model," which provides various intelligent agents to enhance patient services, diagnostic services, departmental management, and hospital operations [10] Group 4 - On August 22, Aike Medical's grism® distal occlusion intracranial thrombectomy stent received approval from the National Medical Products Administration, designed for treating ischemic stroke [13] - The stent features a unique multifunctional design that allows for effective blood flow restoration and thrombosis removal, significantly reducing patient mortality and disability rates [13] Group 5 - Blood Xiji Bio announced on August 22 that its "megakaryocyte injection" new drug clinical trial application received approval from the FDA, marking the first of its kind globally [17] - This product aims to treat thrombocytopenia caused by tumor treatments, potentially benefiting millions of patients annually and representing a significant advancement in the platelet recovery market [17] Group 6 - On August 13, Qihuan Bio announced that its universal dual-target CAR-T cell product QT-019B received FDA approval for clinical trials, targeting refractory systemic lupus erythematosus [18] - This marks the first CAR-T cell product developed by a Chinese company to receive FDA approval for treating autoimmune diseases [18] Group 7 - On July 31, Youtijisheng announced that its LACO-Stim® autologous MSLN CAR-T cell therapy received FDA IND approval for treating MSLN-positive advanced solid tumors [20] - This innovation is based on three core technology platforms, aiming to overcome challenges in solid tumor treatment, which has historically progressed slowly compared to blood cancers [22] Group 8 - The first preloaded dry valve Prostyle A® was successfully implanted in China, marking a significant advancement in transcatheter aortic valve replacement systems [26] - This valve utilizes a leading anti-calcification platform to enhance durability, providing patients with a more reliable treatment option [26] Group 9 - A clinical study evaluating the safety and efficacy of LY-M003 injection for treating Wilson's disease in adolescents was successfully conducted, marking the first gene therapy for this condition in China [30] - The patient showed significant improvement in hemoglobin levels and returned to normal life without adverse reactions [30] Group 10 - On August 26, Zhengxu Bio announced the successful treatment of the first patient with sickle cell disease using its base editing drug CS-101 injection, marking a milestone in gene editing therapy in China [31] - The patient demonstrated sustained improvement in hemoglobin levels and no vaso-occlusive crises post-treatment, indicating the potential of this therapy [31] Group 11 - Sequoia China has invested in over 200 medical and health enterprises with distinctive technological features and high growth potential, covering various sectors including innovative drugs, medical devices, and digital healthcare [33]

Core Viewpoint - The integration of AI in medical imaging is advancing rapidly, with large models evolving from mere tools to core drivers of diagnostic ecosystems, enhancing the workflow of radiologists and addressing challenges in pathology diagnostics [1][2]. Group 1: Development of AI in Medical Imaging - Medical imaging AI models have achieved widespread application in the workflow of radiologists, transitioning from auxiliary diagnostic tools to essential components of the diagnostic ecosystem [1]. - The "Shukun Kun Multi-modal Medical Health Large Model" released by Shukun Technology in April signifies this evolution, enhancing the role of AI in diagnostics [1]. Group 2: Challenges and Solutions in Pathology - Pathology models are considered the "crown jewel" of medical models due to their complexity and diversity, with the first clinical-grade pathology model, "Insight," developed by Tuo Che Future, addressing accuracy and efficiency challenges [2]. - The pathology model addresses long-standing challenges in generalization across hospitals, cancer types, and pathology tasks, simplifying processes and improving diagnostic efficiency [3]. Group 3: Enhancing AI Generalization Performance - AI model generalization is crucial for reliability and stability, with key challenges including insufficient data diversity, model limitations, and the long-tail nature of medical data [4][6]. - Strategies to enhance generalization include expanding data sample diversity, optimizing model training, and iterating models in real clinical environments [6][7]. Group 4: Addressing the Hallucination Problem - The hallucination issue in large models is a significant barrier, with RAG (Retrieval-Augmented Generation) technology proposed as a solution to enhance accuracy by integrating external knowledge [8][9]. - A hybrid approach combining generative and discriminative AI is suggested to mitigate risks in critical decision-making scenarios, ensuring reliable outputs [9]. Group 5: Deployment Trends in Healthcare - Local deployment of AI models is becoming the preferred choice for hospitals due to data privacy and compliance advantages, with integrated solutions like one-box systems gaining traction [10][11]. - One-box systems combine the strengths of general and specialized models, addressing diverse medical needs while ensuring data control [10]. Group 6: Future Trends in Medical AI - The performance of medical large models is surpassing traditional small models, with applications expanding from thousands to over ten thousand hospitals [12]. - The future of medical AI is moving towards multi-modal integration and comprehensive diagnostics, akin to a digital "general practitioner" that synthesizes various patient data for holistic treatment recommendations [12][13].

持续推动医疗影像领域变革。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息， 数坤科技 日前在 CMEF 上亮相了升级后的 "数坤坤" 多模态医疗健康大模型 （以下简称"数坤坤"大模型） 。 依托这一前沿大模型，数坤科技推出了数字人体 4.0技术平台以及平台之上被"数坤坤"大模型全面赋 能升级后的数智影像、数智超声、数智医院、数智基层解决方案，和一系列加载了"数坤坤"能力的AI 原生硬件。 数坤科技创始人、董事长毛新生 表示， 数字人体 4.0将带动医疗健康产业升级进入新阶段，希望通 过数字化的人体，让所有的医生在为病人服务时能拥有跟今天完全不同的智能化手段。数坤在大模型 本身以及模型应用方面，都走在全世界的前列。 作为医疗垂类大模型， "数坤坤"已经可以识别出CT、MR、DR、X-ray、钼靶以及超声等模态的影 像数据，深刻理解患者的生化检查、诊断报告、既往病史和现病史等文本信息。同时，在学习了公域 这种创新模式相当于为医生配备了处理繁琐工作的 "智能助手"，显著提升诊疗效率与质量；同时为 患者提供24小时在线的"专属医生"，实现个性化的健康管 ...

Group 1 - Shenzhen People's Hospital, Shukun Technology, and Huawei have formed a deep collaboration to deploy the DeepSeek-R1 model and the "Shukun Kun" multi-modal healthcare model, enhancing the hospital's medical and research capabilities [3] - The platform equipped with DeepSeek and "Shukun Kun" medical models will provide comprehensive research support, enabling rapid construction of multi-modal databases and offering data analysis tools for researchers [5] - The global first peritoneal dialysis model was launched by Shenzhou Medical and Sun Yat-sen University First Affiliated Hospital, utilizing advanced DHC+DeepSeek dual-engine architecture for precise understanding and processing of complex information in the field [7] Group 2 - Yingxi Intelligent has deployed its first bipedal humanoid robot named "Supervisor" in its AI-driven fully automated drug discovery laboratory, aimed at enhancing laboratory operations [10] - The innovative implantable neurostimulation system by Boruikang has passed the review by the National Medical Products Administration, marking a significant advancement in medical technology [12] - The commercial production base for small nucleic acid drugs by Zhaowei Technology has officially commenced operations, featuring advanced equipment and a total designed capacity of 48 production lines [20] Group 3 - Zhengxu Bio's self-developed base editing drug CS-101 has successfully treated a Malaysian patient with beta-thalassemia, marking another significant achievement in gene editing therapy [23] - The OCT intravascular imaging catheter developed by Weiguang Medical has received registration approval for dual indications, enhancing diagnostic efficiency in coronary and carotid artery diseases [26] - The first platelet-related cell new drug XJ-MK-002 has been granted orphan drug designation by the FDA for treating congenital thrombocytopenia, showcasing innovation in rare disease treatment [28] Group 4 - The new generation PI3Kα inhibitor JYP0035 capsule has received approval for clinical trials, aimed at treating PIK3CA mutated, HR-positive, HER2-negative breast cancer, indicating strong R&D capabilities [30] - The first domestically developed antibacterial fishbone suture line has been approved by the NMPA, representing a breakthrough in surgical materials [43] - The flexible ultrasound probe project led by Suzhou Nolaisheng Technology has been approved as a national key research and development project, highlighting advancements in ultrasound technology [39]